The Apex Times
Above the Noise
Business Wire
BusinessTaiwan moves to criminalize AI chip shipments to China, tightening the squeeze on leading semiconductor firmsThe Apex TimesBusinessWall Street veteran Larry McDonald points to Nike as a potential turnaround as investors worry the market is masking troubleThe Apex TimesBusinessApple and Salesforce top a list of stocks described as trading near “buy points” as AI-led momentum wobblesThe Apex TimesBusinessLeidos extends UK logistics program, wins $56 million U.S. behavioral health research contract, shifting the stock debateThe Apex TimesBusinessNvidia CEO urges investors to look past a brutal tech selloff, saying “all of this is going to pass”The Apex TimesBusinessIntel’s data-center rebound and valuation get fresh bullish framing for 2027The Apex TimesBusinessBoeing shares gain attention as analysts flag its role in next phase of U.S. air powerThe Apex TimesBusinessDisney’s ‘Lion King’ casting offer from the early 1990s resurfaced, reigniting a long-running conversation about royaltiesThe Apex TimesBusinessJohnson & Johnson lifts sales outlook again, but the bigger test is how investors read its Q3 reportThe Apex TimesBusinessBerkshire Hathaway’s Greg Abel adds to his latest technology bet in Bending Spoons, according to market coverageThe Apex TimesBusinessMeta regains momentum, analysts say, as AI agent and frontier model roll out draws early praiseThe Apex TimesBusinessCoca-Cola vs. Duke Energy dividend debate highlights yield gap and long-term income assumptionsThe Apex TimesBusinessTaiwan moves to criminalize AI chip shipments to China, tightening the squeeze on leading semiconductor firmsThe Apex TimesBusinessWall Street veteran Larry McDonald points to Nike as a potential turnaround as investors worry the market is masking troubleThe Apex TimesBusinessApple and Salesforce top a list of stocks described as trading near “buy points” as AI-led momentum wobblesThe Apex TimesBusinessLeidos extends UK logistics program, wins $56 million U.S. behavioral health research contract, shifting the stock debateThe Apex TimesBusinessNvidia CEO urges investors to look past a brutal tech selloff, saying “all of this is going to pass”The Apex TimesBusinessIntel’s data-center rebound and valuation get fresh bullish framing for 2027The Apex TimesBusinessBoeing shares gain attention as analysts flag its role in next phase of U.S. air powerThe Apex TimesBusinessDisney’s ‘Lion King’ casting offer from the early 1990s resurfaced, reigniting a long-running conversation about royaltiesThe Apex TimesBusinessJohnson & Johnson lifts sales outlook again, but the bigger test is how investors read its Q3 reportThe Apex TimesBusinessBerkshire Hathaway’s Greg Abel adds to his latest technology bet in Bending Spoons, according to market coverageThe Apex TimesBusinessMeta regains momentum, analysts say, as AI agent and frontier model roll out draws early praiseThe Apex TimesBusinessCoca-Cola vs. Duke Energy dividend debate highlights yield gap and long-term income assumptionsThe Apex TimesBusinessTaiwan moves to criminalize AI chip shipments to China, tightening the squeeze on leading semiconductor firmsThe Apex TimesBusinessWall Street veteran Larry McDonald points to Nike as a potential turnaround as investors worry the market is masking troubleThe Apex TimesBusinessApple and Salesforce top a list of stocks described as trading near “buy points” as AI-led momentum wobblesThe Apex TimesBusinessLeidos extends UK logistics program, wins $56 million U.S. behavioral health research contract, shifting the stock debateThe Apex TimesBusinessNvidia CEO urges investors to look past a brutal tech selloff, saying “all of this is going to pass”The Apex TimesBusinessIntel’s data-center rebound and valuation get fresh bullish framing for 2027The Apex TimesBusinessBoeing shares gain attention as analysts flag its role in next phase of U.S. air powerThe Apex TimesBusinessDisney’s ‘Lion King’ casting offer from the early 1990s resurfaced, reigniting a long-running conversation about royaltiesThe Apex TimesBusinessJohnson & Johnson lifts sales outlook again, but the bigger test is how investors read its Q3 reportThe Apex TimesBusinessBerkshire Hathaway’s Greg Abel adds to his latest technology bet in Bending Spoons, according to market coverageThe Apex TimesBusinessMeta regains momentum, analysts say, as AI agent and frontier model roll out draws early praiseThe Apex TimesBusinessCoca-Cola vs. Duke Energy dividend debate highlights yield gap and long-term income assumptionsThe Apex TimesBusinessTaiwan moves to criminalize AI chip shipments to China, tightening the squeeze on leading semiconductor firmsThe Apex TimesBusinessWall Street veteran Larry McDonald points to Nike as a potential turnaround as investors worry the market is masking troubleThe Apex TimesBusinessApple and Salesforce top a list of stocks described as trading near “buy points” as AI-led momentum wobblesThe Apex TimesBusinessLeidos extends UK logistics program, wins $56 million U.S. behavioral health research contract, shifting the stock debateThe Apex TimesBusinessNvidia CEO urges investors to look past a brutal tech selloff, saying “all of this is going to pass”The Apex TimesBusinessIntel’s data-center rebound and valuation get fresh bullish framing for 2027The Apex TimesBusinessBoeing shares gain attention as analysts flag its role in next phase of U.S. air powerThe Apex TimesBusinessDisney’s ‘Lion King’ casting offer from the early 1990s resurfaced, reigniting a long-running conversation about royaltiesThe Apex TimesBusinessJohnson & Johnson lifts sales outlook again, but the bigger test is how investors read its Q3 reportThe Apex TimesBusinessBerkshire Hathaway’s Greg Abel adds to his latest technology bet in Bending Spoons, according to market coverageThe Apex TimesBusinessMeta regains momentum, analysts say, as AI agent and frontier model roll out draws early praiseThe Apex TimesBusinessCoca-Cola vs. Duke Energy dividend debate highlights yield gap and long-term income assumptionsThe Apex Times
Back to front
Jim Cramer Highlights Moderna as Market Rotation Focus Turns to Biopharma
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jul 4, 10:45 AM EDT

Jim Cramer Highlights Moderna as Market Rotation Focus Turns to Biopharma

On CNBC’s Mad Money, the host pointed to Moderna’s recent share performance while discussing a broader shift in investor attention across sectors.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Moderna (NASDAQ:MRNA) drew a spotlight from Jim Cramer as he discussed how investors might position for what he described as Wednesday’s market rotation. In comments carried by Yahoo Finance, Cramer singled out Moderna among several stocks he referenced during his segment, saying he “for the first time in ages” liked having a position in the company.

The remarks came in the context of Cramer advising viewers on potential opportunities tied to changing market leadership. According to the Yahoo Finance report, he highlighted Moderna’s significant stock gains over the period he was discussing, using that momentum as part of his rationale for revisiting interest in the name.

Cramer’s comment is notable less for new Moderna-specific operational details and more for what it indicates about sentiment. In market talk, prominent hosts often influence retail attention, especially when they tie a single stock to broader tactical themes like rotation between growth, value, and other crowded categories.

For investors, the immediate takeaway is that Moderna’s recent performance helped put it back on the radar of a widely followed television personality. However, the Yahoo Finance piece does not provide new information about Moderna’s pipeline, trial updates, manufacturing progress, or financial guidance. It also does not spell out a specific catalyst, beyond the stock’s gains, that prompted Cramer’s shift in tone.

Biopharma stocks often react not only to company fundamentals, but also to risk appetite and the relative attractiveness of healthcare versus other sectors. When rotation themes move capital, higher-beta healthcare names can catch incremental flows, even if no new trial result or regulatory decision is announced in the same news window.

Still, what Moderna did or did not disclose in response to the moment is unclear from the available reporting. The Yahoo Finance post summarized Cramer’s television comments but did not include details such as the specific dates over which the gains occurred, whether he referenced any particular program within Moderna’s portfolio, or any expectations for near-term milestones.

Why It Matters

  • High-profile media commentary can affect near-term trading interest, particularly for broadly held, liquid equities like Moderna.
  • A “rotation” narrative suggests investors may be reallocating attention across sectors, with healthcare names benefiting when sentiment improves.
  • Without a disclosed catalyst, the focus remains on price action and sentiment rather than incremental company fundamentals in this specific moment.

Sources

Key Facts

  • Jim Cramer discussed Moderna (NASDAQ:MRNA) during a segment focused on Wednesday’s market rotation.
  • Cramer said he “for the first time in ages” liked having a position in Moderna.
  • The Yahoo Finance report attributes the renewed attention partly to Moderna’s significant gains over the relevant recent period.
  • The report does not describe any new Moderna corporate or clinical developments in connection with the comments.

Healthcare Related

Jim Cramer Highlights Moderna as Market Rotation Focus Turns to Biopharma | The Apex Times